Rosuvastatin prevents MRLC dephosphorylation in VSMC exposed to LDL.

<p>(<b>A</b>) Representative 2-DE gel of the cytoskeleton/membrane fraction. Arrows show spots identified as MYL9 (sarcomeric-MRLC), non-sarcomeric-MRLC (MRLC) and alkali-MLC (MLC). Enlarged images for the proteomic pattern of the non-sarcomeric MRLC isoforms (MRLC-2, spot 1–2 and MRLC-3 spots 3–4). Note that numbers 1–2 and 3–4 denote double spots with different p<i>I</i> of the non-sarcomeric MRLC isoforms. (<b>B</b>) Bar-diagrams for ratios between the intensity of the spot with lower p<i>I</i> and the correspondent with higher p<i>I</i>. Results given as mean±SEM (n=3). P values for Man-Whitney test; only shown differences for P<0.05 (<b>C</b>) Western blot for phosporylated-MRLC (P-MRLC) and total MRLC in extracts of VSMC exposed to agLDL in the presence of different dose of rosuvastatin (2.5–10 µM). C denotes the control group. Bar diagram represents quantitative values (mean±SEM) of 3 independent experiments. P values for Man-Whitney test.